A



Factors	N	HR	95%CI
All Patients	377	0.73	0.57-0.93
Geographic region: Europe	171	0.65	0.46-0.93
Geographic region: Asia	162	0.86	0.59-1.24
Geographic region: Rest of the World	44	0.71	0.36-1.41
ECOG performance status:0/1	343	0.74	0.58-0.96
ECOG performance status:2	34	0.52	0.24-1.11
Prior bevacizumab exposure for mCRC: yes	120	0.55	0.36-0.84
Prior bevacizumab exposure for mCRC: no	257	0.85	0.63-1.14
Location of primary tumor: Colon	214	0.73	0.54-1.00
Location of primary tumor: Rectal	162	0.74	0.51-1.08
Number of sites of metastatic disease: 1	79	0.71	0.41-1.24
Number of sites of metastatic disease: 2	131	0.95	0.63-1.43
Number of sites of metastatic disease: ≥ 3	167	0.59	0.42-0.84
Location of sites of metastatic disease: Liver only	38	0.82	0.39-1.76
Location of sites of metastatic disease: Other sites +/- liver	339	0.73	0.57-0.94
Baseline LDH ≥ 2.0 x Upper Limit: < 2xULN	269	0.73	0.54-0.99
Baseline LDH ≥ 2.0 x Upper Limit: ≥ 2xULN	100	0.40	0.26-0.62
Baseline age group (cutoff of 65): < 65	241	0.78	0.58-1.06
Baseline age group (cutoff of 65): ≥ 65	136	0.68	0.46-1.00
Sex: Male	216	0.74	0.54-1.01
Sex: Female	161	0.72	0.49-1.04
Race: White	209	0.68	0.50-0.94
Race: All other categories	168	0.81	0.56-1.17

B



Factors	N	HR	95%CI
All Patients	270	0.70	0.53-0.93
Geographic region: Europe	121	0.62	0.41-0.94
Geographic region: Asia	114	0.84	0.54-1.30
Geographic region: Rest of the World	35	0.60	0.28-1.26
ECOG performance status:0/1	244	0.72	0.54-0.97
ECOG performance status:2	26	0.34	0.14-0.81
Prior bevacizumab exposure for mCRC: yes	82	0.55	0.33-0.91
Prior bevacizumab exposure for mCRC: no	188	0.77	0.55-1.09
Location of primary tumor: Colon	160	0.76	0.53-1.08
Location of primary tumor: Rectal	109	0.58	0.37-0.91
Number of sites of metastatic disease: 1	56	0.68	0.36-1.30
Number of sites of metastatic disease: 2	97	0.80	0.50-1.28
Number of sites of metastatic disease: ≥ 3	117	0.64	0.43-0.98
Location of sites of metastatic disease: Liver only	30	0.79	0.33-1.89
Location of sites of metastatic disease: Other sites +/- liver	240	0.69	0.51-0.93
Baseline LDH ≥ 2.0 x Upper Limit: < 2xULN	186	0.69	0.48-0.99
Baseline LDH ≥ 2.0 x Upper Limit: ≥ 2xULN	78	0.27	0.16-0.46
Baseline age group (cutoff of 65): < 65	172	0.74	0.52-1.06
Baseline age group (cutoff of 65): ≥ 65	98	0.59	0.37-0.94
Sex: Male	157	0.70	0.49-1.01
Sex: Female	113	0.68	0.43-1.06
Race: White	153	0.62	0.43-0.90
Race: All other categories	117	0.82	0.53-1.27